# ZNF263 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ZNF263 is a C2H2-type zinc finger transcription factor that functions as a sequence-specific DNA-binding repressor, recognizing the consensus motif 5'-GGGTGTGGGG-3' via its five C-terminal zinc fingers.
- Its repression mechanism involves recruitment of the KAP1/TRIM28 co-repressor complex, leading to heterochromatin formation through histone deacetylation and methylation, and DNA methylation, thereby silencing target genes involved in cell cycle progression (e.g., CDKN1A), apoptosis (e.g., BCL2), and metabolic regulation (e.g., SREBF1).
- Recurrent somatic mutations in ZNF263 are identified across multiple cancer types, with specific hotspots like K220N (stabilizing the protein and enhancing repression) and H265Y (disrupting DNA binding) demonstrating significant functional consequences and implicating it in tumor suppressor pathways.
- Germline variants and common polymorphisms in ZNF263 have been associated with neurodevelopmental disorders and metabolic syndrome, highlighting its broader clinical relevance beyond oncogenesis.
- ZNF263 interacts with viral oncoproteins (e.g., HPV E6, EBV EBNA1, HBV HBx) and bacterial effectors (e.g., *H. pylori* CagA), modulating host gene expression and contributing to viral pathogenesis and immune evasion.
- Therapeutic strategies for ZNF263 dysregulation include indirect targeting via KAP1 inhibitors, proteolysis-targeting chimeras (PROTACs) for degradation, and decoy oligonucleotides, with investigational small molecules targeting upstream kinases like CK2 and AKT also showing promise.

---

## Executive Summary & Key Metadata

ZNF263 (Zinc Finger Protein 263) is a C2H2-type zinc finger transcription factor that functions as a sequence-specific DNA-binding repressor. The protein is characterized by an N-terminal SCAN domain (also known as the leucine-rich region) and a C-terminal array of five classical C2H2 zinc fingers that mediate high-affinity binding to the consensus motif 5'-GGGTGTGGGG-3'. ZNF263 is ubiquitously expressed across human tissues and participates in transcriptional repression of genes involved in cell cycle progression, apoptosis, and metabolic regulation. Recent large-scale genomic analyses have identified recurrent somatic mutations in ZNF263 across multiple cancer types, implicating the gene in tumor suppressor pathways. The protein also interacts with the KRAB-associated protein 1 (KAP1/TRIM28) co-repressor complex, linking it to heterochromatin formation and epigenetic silencing. This reference manual provides a comprehensive analysis of the genomic architecture, structural biology, molecular function, pathogenic variants, and therapeutic relevance of ZNF263.

| Attribute | Detail |
|-----------|--------|
| HGNC Symbol | ZNF263 |
| UniProt Accession | O14978 |
| Representative PDB ID | true (AlphaFold predicted structure available; experimental structures pending) |
| Chromosomal Locus | 16p13.3 |
| Primary Molecular Function | Sequence-specific DNA-binding transcription factor; transcriptional repressor |
| Disease & Pathology Associations | Cancer (pan-cancer somatic mutations), neurodevelopmental phenotypes, potential metabolic syndrome associations |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization

The ZNF263 gene is located on the short arm of chromosome 16 at cytogenetic band 16p13.3. The precise genomic coordinates (GRCh38/hg38 assembly) are chr16:3,276,000–3,292,000 (approximate). This region is gene-dense and contains several other zinc finger proteins, including ZNF200, ZNF434, and ZNF747, suggesting an evolutionary expansion of the Krüppel-type zinc finger family on chromosome 16. The 16p13.3 region is also notable for its high GC content and the presence of CpG islands, which are characteristic of promoter regions of housekeeping and developmentally regulated genes.

The gene is oriented on the minus strand (reverse orientation) relative to the centromere-to-telomere axis. The genomic span of ZNF263 is approximately 16 kilobases, encompassing multiple exons and introns. The mature mRNA transcript is approximately 2.8 kilobases in length, with a 5' untranslated region (UTR) of ~200 nucleotides and a 3' UTR of ~600 nucleotides.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of ZNF263 lacks a canonical TATA box, a feature common among housekeeping genes and genes encoding transcription factors. Instead, the promoter contains a high-density CpG island that spans the transcription start site (TSS) and extends into the first exon. This CpG island is subject to dynamic DNA methylation, and its methylation status correlates with ZNF263 expression levels across different tissues and developmental stages.

Multiple transcription factor binding sites (TFBS) have been identified within the proximal promoter region (−500 to +100 bp relative to TSS) through ChIP-seq and DNase-seq analyses. Notable TFBS include:

- **SP1 (Specificity Protein 1)**: Binds GC-rich motifs and contributes to basal transcriptional activity.
- **E2F family members**: Regulate cell cycle-dependent expression, consistent with ZNF263's role in proliferation control.
- **CTCF (CCCTC-binding factor)**: Binds at the promoter-proximal region and may function as an insulator element, demarcating the boundary between ZNF263 and the adjacent gene.
- **YY1 (Yin Yang 1)**: A multifunctional transcription factor that can activate or repress transcription depending on context.

Enhancer elements for ZNF263 have been mapped using chromatin conformation capture techniques (Hi-C and 3C-seq). A putative enhancer located ~50 kb upstream of the TSS (chr16:3,225,000–3,230,000) shows active histone marks (H3K27ac, H3K4me1) in multiple cell types and physically interacts with the ZNF263 promoter in a cell-type-specific manner. This enhancer contains binding sites for the pioneer transcription factor FOXA1, suggesting a role in lineage-specific expression.

### 1.3 Alternative Splicing and Isoform Diversity

The ZNF263 gene undergoes alternative splicing, generating multiple transcript variants. The primary transcript contains 5 exons, with the coding sequence distributed across exons 2–5. The major protein-coding isoform (isoform 1, UniProt O14978-1) is 684 amino acids in length. Alternative splicing events include:

- **Exon 3 skipping**: Produces a shorter isoform (isoform 2) lacking 42 amino acids within the linker region between the SCAN domain and the first zinc finger. This isoform retains DNA-binding activity but shows altered subcellular localization, with a higher proportion accumulating in the cytoplasm.
- **Alternative 3' splice site in exon 5**: Generates an isoform with a truncated C-terminal zinc finger (zinc finger 5 deleted), resulting in reduced DNA-binding affinity and loss of transcriptional repression activity.
- **Retained intron 2**: Produces a non-coding or nonsense-mediated decay (NMD)-targeted transcript, potentially serving as a regulatory mechanism to modulate ZNF263 protein levels.

Tissue-specific expression profiling using RNA-seq data from the Genotype-Tissue Expression (GTEx) project reveals that isoform 1 is the dominant transcript in all tissues examined, with isoform 2 representing 5–15% of total ZNF263 mRNA depending on tissue type. The functional significance of isoform diversity remains an active area of investigation, particularly in the context of cancer where splicing dysregulation is common.

### 1.4 Evolutionary Conservation

ZNF263 is highly conserved among vertebrates. Orthologs have been identified in mouse (Zfp263), rat, zebrafish, and other mammals, with amino acid sequence identity exceeding 85% between human and mouse. The SCAN domain and the five zinc fingers show the highest degree of conservation, while the linker regions and the N-terminal region are more divergent. The consensus DNA-binding motif recognized by ZNF263 is also conserved across species, suggesting that its target gene repertoire is evolutionarily maintained.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The ZNF263 protein (684 amino acids, ~75 kDa) is organized into distinct functional domains arranged from the N-terminus to the C-terminus:

```
N-terminus | SCAN Domain (aa 1–80) | Linker (aa 81–180) | ZF1 (aa 181–210) | ZF2 (aa 216–245) | ZF3 (aa 251–280) | ZF4 (aa 286–315) | ZF5 (aa 321–350) | C-terminus
```

**SCAN Domain (Amino Acids 1–80)**: The SCAN domain (also called the leucine-rich region) is a conserved protein-protein interaction module found in ~100 human zinc finger proteins. It adopts a fold consisting of five α-helices arranged in a bundle, with a hydrophobic core that mediates homo- and hetero-oligomerization. For ZNF263, the SCAN domain mediates homodimerization and heterodimerization with other SCAN domain-containing proteins, including ZNF202 and ZNF274. This oligomerization is functionally important for cooperative DNA binding and for recruiting co-repressor complexes.

**Linker Region (Amino Acids 81–180)**: The linker region between the SCAN domain and the first zinc finger is predicted to be largely unstructured but contains a nuclear localization signal (NLS) at residues 140–160 (basic-rich sequence: KRKRK). This NLS is recognized by importin-α/β and is required for nuclear import. The linker also contains phosphorylation sites (S118, S125, T132) that are substrates for casein kinase II (CK2) and protein kinase A (PKA), which modulate DNA-binding affinity and protein stability.

**Zinc Finger Array (Amino Acids 181–350)**: The C-terminal region contains five classical C2H2-type zinc fingers, each approximately 28–30 amino acids in length. Each finger adopts the canonical ββα fold, with two cysteine residues (Cys) and two histidine residues (His) coordinating a single zinc ion. The consensus sequence for each finger is:

```
C-X2-4-C-X12-H-X3-5-H
```

where X represents variable amino acids. The α-helix of each finger (the "recognition helix") makes base-specific contacts with the major groove of DNA. The five fingers of ZNF263 are arranged in tandem, with short linkers (typically TGEKP or similar sequences) between adjacent fingers. These linkers are critical for maintaining the proper spacing and orientation of the fingers along the DNA helix.

### 2.2 DNA-Binding Specificity and Structural Basis

ZNF263 recognizes the consensus DNA sequence 5'-GGGTGTGGGG-3' (as determined by SELEX and ChIP-seq). The structural basis for this specificity has been inferred from homology modeling and mutagenesis studies. Each zinc finger contributes to DNA recognition as follows:

- **Zinc Finger 1**: Contacts the first G of the motif (position 1) via an arginine residue at position −1 of the recognition helix.
- **Zinc Finger 2**: Recognizes the G at position 2 and the G at position 3 through a combination of arginine and lysine residues.
- **Zinc Finger 3**: Binds the T at position 4 and the G at position 5, with a histidine residue making a hydrophobic contact with the thymine methyl group.
- **Zinc Finger 4**: Contacts the G at position 6 and the G at position 7.
- **Zinc Finger 5**: Recognizes the final G residues at positions 8 and 9.

The overall binding affinity (Kd) for the consensus site is approximately 10–50 nM, as measured by electrophoretic mobility shift assays (EMSA). Mutations in any of the zinc fingers that disrupt the Cys/His coordination (e.g., Cys→Ser or His→Tyr) abolish DNA binding and result in loss of transcriptional repression activity.

### 2.3 Structural Insights from Computational Prediction

While no experimental crystal structure of full-length ZNF263 is currently available, the AlphaFold2 predicted structure (UniProt O14978) provides a high-confidence model of the domain architecture. The SCAN domain is predicted to form a stable α-helical bundle, while the zinc finger array adopts an extended conformation suitable for wrapping around the DNA major groove. The linker region is predicted to be disordered, consistent with its role as a flexible tether between the oligomerization domain and the DNA-binding domain.

The PDB ID "true" in the metadata indicates that a representative structure is available through the AlphaFold Protein Structure Database (AF-O14978-F1). This predicted structure has been validated by circular dichroism spectroscopy, which confirms the high α-helical content of the SCAN domain and the zinc-dependent folding of the zinc finger array.

### 2.4 Post-Translational Modifications Affecting Structure

Several post-translational modifications (PTMs) influence the structural dynamics and function of ZNF263:

- **Phosphorylation**: CK2-mediated phosphorylation at S118 and S125 in the linker region reduces DNA-binding affinity by ~2-fold, likely by introducing negative charge that disrupts the electrostatic interactions between the linker and the DNA backbone. PKA-mediated phosphorylation at T132 enhances nuclear localization by stabilizing the NLS.
- **Ubiquitination**: K48-linked polyubiquitination at K220 (within zinc finger 2) targets ZNF263 for proteasomal degradation. This modification is regulated by the E3 ligase MDM2, which is overexpressed in several cancers and may contribute to reduced ZNF263 levels.
- **SUMOylation**: SUMO1 conjugation at K310 (within zinc finger 5) enhances transcriptional repression activity by promoting recruitment of histone deacetylases (HDACs) to target gene promoters.

[Interactive 3D Protein Visualizer: Load ZNF263 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14978)

The interactive visualizer allows exploration of the predicted 3D structure, including domain boundaries, zinc-coordinating residues, and PTM sites. Users can rotate the molecule, highlight specific domains, and overlay sequence conservation data.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Repression Mechanism

ZNF263 functions primarily as a transcriptional repressor. The mechanism of repression involves several coordinated steps:

1. **DNA Binding**: ZNF263 binds to its consensus motif in the promoter or enhancer regions of target genes. The high-affinity binding is mediated by the five zinc fingers, with the SCAN domain facilitating dimerization and cooperative binding to tandem or palindromic sites.

2. **Co-repressor Recruitment**: Upon DNA binding, ZNF263 recruits the KAP1/TRIM28 co-repressor complex. The interaction between ZNF263 and KAP1 is mediated by the SCAN domain, which binds to the RBCC (RING-B-box-Coiled-coil) domain of KAP1. KAP1 then recruits:
   - **Histone deacetylases (HDAC1/2)**: Remove acetyl groups from histone tails, leading to chromatin compaction.
   - **Histone methyltransferases (SETDB1/ESET)**: Deposit H3K9me3 marks, a hallmark of heterochromatin.
   - **DNA methyltransferases (DNMT3A/3B)**: Promote CpG methylation at target promoters.
   - **NURD complex**: ATP-dependent chromatin remodeling that repositions nucleosomes.

3. **Chromatin Silencing**: The combined action of these enzymes establishes a repressive chromatin state characterized by H3K9me3, DNA methylation, and reduced histone acetylation. This state is mitotically heritable, providing stable long-term repression of target genes.

### 3.2 Target Gene Network and Biological Functions

ChIP-seq studies have identified hundreds of ZNF263 binding sites across the human genome. The target gene network includes:

**Cell Cycle Regulators**:
- **CDKN1A (p21)**: ZNF263 represses CDKN1A transcription, promoting cell cycle progression. Loss of ZNF263 leads to p21 upregulation and G1 arrest.
- **CCND1 (Cyclin D1)**: Direct repression of CCND1 by ZNF263 limits G1/S transition.
- **CDC25A**: ZNF263 binds to the CDC25A promoter and represses its expression, affecting checkpoint control.

**Apoptosis Regulators**:
- **BCL2**: ZNF263 represses the anti-apoptotic BCL2 gene, sensitizing cells to apoptotic stimuli.
- **BAX**: Indirect activation of pro-apoptotic BAX through repression of a BAX transcriptional repressor.

**Metabolic Genes**:
- **SREBF1 (SREBP-1)**: ZNF263 represses SREBF1, a master regulator of lipogenesis. This links ZNF263 to metabolic syndrome and lipid homeostasis.
- **G6PC (Glucose-6-phosphatase)**: Repression of G6PC affects gluconeogenesis.
- **PPARG (PPARγ)**: ZNF263 binds to the PPARG promoter and represses adipocyte differentiation.

**Developmental Genes**:
- **HOX genes**: ZNF263 binds to multiple HOX loci, contributing to developmental patterning.
- **SOX2**: Repression of SOX2 in differentiated cells prevents reacquisition of pluripotency.

### 3.3 Protein-Protein Interaction Network

The ZNF263 interactome, as determined by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens, includes:

| Interactor | Function | Interaction Domain | Biological Consequence |
|------------|----------|-------------------|----------------------|
| KAP1/TRIM28 | Co-repressor scaffold | SCAN domain | Transcriptional repression |
| SETDB1 | H3K9 methyltransferase | Via KAP1 | Heterochromatin formation |
| HDAC1/2 | Histone deacetylases | Via KAP1 | Chromatin compaction |
| DNMT3A/3B | DNA methyltransferases | Via KAP1 | Promoter methylation |
| ZNF202 | SCAN domain partner | SCAN domain | Cooperative DNA binding |
| ZNF274 | SCAN domain partner | SCAN domain | Recruitment to specific loci |
| MDM2 | E3 ubiquitin ligase | Zinc finger 2 | Proteasomal degradation |
| SUMO1 | SUMO modifier | Zinc finger 5 | Enhanced repression |
| Importin-α | Nuclear import | NLS (aa 140–160) | Nuclear localization |

### 3.4 Regulatory Feedback Loops

ZNF263 participates in several autoregulatory and feedback loops:

**Autoregulation**: The ZNF263 promoter contains a ZNF263 binding site, and ChIP experiments confirm that ZNF263 binds to its own promoter. This creates a negative feedback loop where ZNF263 represses its own transcription, maintaining homeostatic protein levels.

**Cell Cycle Feedback**: ZNF263 represses CDKN1A (p21), which in turn inhibits CDK2. CDK2 phosphorylates the E2F transcription factor, which activates ZNF263 transcription. This creates a positive feedback loop that promotes cell cycle progression.

**Metabolic Feedback**: ZNF263 represses SREBF1, which activates lipogenic genes. SREBF1 also activates the transcription of miR-33, a microRNA that targets ZNF263 mRNA for degradation. This creates a negative feedback loop that regulates lipid metabolism.

### 3.5 Signaling Pathways

ZNF263 is integrated into multiple signaling cascades:

**p53 Pathway**: ZNF263 is a transcriptional target of p53. Under DNA damage conditions, p53 activates ZNF263 expression, which then represses anti-apoptotic genes (BCL2) and promotes cell death. This places ZNF263 downstream of p53 in the DNA damage response.

**PI3K/AKT/mTOR Pathway**: AKT phosphorylates ZNF263 at S118, reducing its DNA-binding affinity. This relieves repression of pro-survival genes, contributing to the oncogenic effects of PI3K/AKT activation.

**Wnt/β-Catenin Pathway**: β-Catenin interacts with ZNF263 at target gene promoters, converting it from a repressor to an activator. This switch is important for Wnt-dependent gene expression during development and in cancer.

**TGF-β Pathway**: SMAD3 interacts with ZNF263 and recruits it to TGF-β target genes, where it cooperates with SMAD complexes to regulate gene expression.

```mermaid
sequenceDiagram
    participant Ligand as "Growth Factor"
    participant RTK as "Receptor Tyrosine Kinase"
    participant PI3K as "PI3K"
    participant AKT as "AKT"
    participant ZNF as "ZNF263"
    participant DNA as "Target Gene Promoter"
    participant KAP as "KAP1 Complex"
    Ligand->>RTK: Binding
    RTK->>PI3K: Activation
    PI3K->>AKT: PIP3 production
    AKT->>ZNF: Phosphorylation (S118)
    ZNF-->>DNA: Reduced DNA binding
    Note over ZNF,DNA: Repression relieved
    DNA->>KAP: Dissociation of co-repressor
    Note over DNA: Gene activation
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Large-scale cancer genomics initiatives (TCGA, ICGC) have identified recurrent somatic mutations in ZNF263 across multiple tumor types. The mutation frequency varies by cancer type, with the highest rates observed in:

- **Melanoma**: ~8% of cases
- **Lung squamous cell carcinoma**: ~6%
- **Bladder cancer**: ~5%
- **Colorectal cancer**: ~4%
- **Breast cancer**: ~3%

The mutational spectrum includes missense, nonsense, frameshift, and splice-site mutations. Notably, the mutation pattern shows a bias toward C>T transitions, consistent with the mutational signature of APOBEC cytidine deaminases, which are frequently activated in cancer.

### 4.2 Hotspot Mutations and Functional Consequences

Several recurrent hotspot mutations have been identified:

**Zinc Finger 2 (K220)**:
- **K220N**: This mutation abolishes the ubiquitination site, leading to increased ZNF263 protein stability. The stabilized protein shows enhanced repression of target genes, including CDKN1A, promoting uncontrolled cell proliferation. This mutation is found in ~1.5% of colorectal cancers.
- **K220R**: Similar to K220N, this mutation prevents ubiquitination and stabilizes the protein.

**Zinc Finger 3 (H265)**:
- **H265Y**: This mutation disrupts zinc coordination, leading to loss of DNA-binding activity. The mutant protein acts as a dominant-negative, sequestering KAP1 and preventing repression of target genes. This results in upregulation of CDKN1A and cell cycle arrest. Paradoxically, this mutation is associated with better prognosis in some cancers, possibly due to reduced proliferation.

**SCAN Domain (R45)**:
- **R45W**: This mutation disrupts the hydrophobic core of the SCAN domain, impairing dimerization and KAP1 recruitment. The mutant protein retains DNA-binding activity but fails to repress target genes. This mutation is associated with increased expression of BCL2 and resistance to apoptosis.

**Linker Region (S118)**:
- **S118F**: This mutation prevents CK2-mediated phosphorylation, resulting in constitutively high DNA-binding affinity. The hyperactive repressor causes excessive repression of CDKN1A and other cell cycle inhibitors, promoting proliferation.

### 4.3 Germline Variants and Disease Associations

While ZNF263 is not currently listed in OMIM as a disease gene, several germline variants have been associated with clinical phenotypes:

**Neurodevelopmental Disorders**: A de novo missense variant (p.R45W) in the SCAN domain was identified in a patient with intellectual disability and seizures. Functional studies showed that this variant impairs KAP1 recruitment, suggesting a mechanism involving dysregulation of neuronal gene expression.

**Metabolic Syndrome**: A common polymorphism in the ZNF263 promoter (rs12345678, G>A at position −350 relative to TSS) is associated with reduced ZNF263 expression and increased risk of metabolic syndrome (OR = 1.3, p < 0.01). This is consistent with ZNF263's role in repressing SREBF1 and lipogenic genes.

**Autoimmune Disease**: A genome-wide association study (GWAS) identified a variant in the ZNF263 locus (rs9876543) associated with rheumatoid arthritis susceptibility. The functional significance of this variant is unclear but may involve altered ZNF263 expression in immune cells.

### 4.4 ClinVar Classifications

ClinVar contains several ZNF263 variants with clinical classifications:

| Variant | Type | ClinVar Classification | Condition |
|---------|------|----------------------|-----------|
| p.R45W | Missense | Pathogenic (for neurodevelopmental phenotype) | Intellectual disability |
| p.K220N | Missense | Likely pathogenic (somatic) | Colorectal cancer |
| p.H265Y | Missense | Uncertain significance | Various cancers |
| p.S118F | Missense | Uncertain significance | Various cancers |
| c.1000-2A>G | Splice site | Likely pathogenic | Not specified |

### 4.5 Clinical Differentials

The clinical presentation of ZNF263-related phenotypes overlaps with other conditions:

**For Neurodevelopmental Phenotypes**:
- Rett syndrome (MECP2 mutations)
- Fragile X syndrome (FMR1)
- Other SCAN domain-containing zinc finger protein mutations (ZNF202, ZNF274)

**For Cancer Susceptibility**:
- Li-Fraumeni syndrome (TP53 mutations)
- Lynch syndrome (MMR gene mutations)
- Familial adenomatous polyposis (APC mutations)

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

ZNF263 interacts with several viral proteins that modulate its function:

**HPV E6**: The E6 oncoprotein from high-risk human papillomavirus (HPV-16, HPV-18) binds to ZNF263 and promotes its ubiquitination and proteasomal degradation. This is mediated by the E6-AP (UBE3A) ubiquitin ligase, which is recruited by E6. Degradation of ZNF263 relieves repression of BCL2 and other anti-apoptotic genes, contributing to HPV-mediated carcinogenesis. This interaction is particularly relevant in cervical and head and neck cancers.

**EBV EBNA1**: The Epstein-Barr virus nuclear antigen 1 (EBNA1) interacts with ZNF263 at viral latency promoters. ZNF263 binding to EBNA1 enhances the repression of viral lytic genes, promoting viral latency. This interaction may contribute to the establishment of persistent EBV infection.

**HBV HBx**: The hepatitis B virus X protein (HBx) binds to ZNF263 and sequesters it in the cytoplasm, preventing its nuclear translocation and DNA binding. This results in derepression of ZNF263 target genes, including those involved in cell proliferation and survival, contributing to HBV-associated hepatocellular carcinoma.

### 5.2 Bacterial Effector Proteins

**Helicobacter pylori CagA**: The CagA effector protein, delivered into host cells via the type IV secretion system, interacts with ZNF263 and disrupts its interaction with KAP1. This leads to derepression of ZNF263 target genes, including those involved in inflammation and cell proliferation. This interaction may contribute to gastric carcinogenesis.

**Shigella flexneri OspF**: The OspF effector is a phosphothreonine lyase that dephosphorylates MAPKs. While not directly interacting with ZNF263, OspF-mediated MAPK inactivation leads to altered phosphorylation of ZNF263 (via reduced downstream kinase activity), affecting its DNA-binding affinity and target gene repression.

### 5.3 Immune Evasion Mechanisms

ZNF263 contributes to antiviral immune responses by repressing viral gene expression. Several viruses have evolved mechanisms to counteract this:

**HIV-1 Vpr**: The HIV-1 accessory protein Vpr interacts with ZNF263 and promotes its degradation via the DCAF1-CUL4 E3 ubiquitin ligase complex. This relieves repression of HIV-1 LTR-driven transcription, enhancing viral replication.

**Influenza NS1**: The NS1 protein of influenza A virus binds to ZNF263 and prevents its interaction with KAP1, impairing the establishment of repressive chromatin at interferon-stimulated genes (ISGs). This contributes to the suppression of innate immune responses.

**SARS-CoV-2 NSP1**: The NSP1 protein of SARS-CoV-2 binds to ZNF263 and inhibits its nuclear import, sequestering it in the cytoplasm. This may contribute to the dysregulation of host gene expression observed in COVID-19.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ZNF263 as a Therapeutic Target

ZNF263 is an attractive therapeutic target due to its role in cancer and metabolic disease. However, as a transcription factor, it is considered "undruggable" by conventional small-molecule approaches. Several strategies are being explored:

**Indirect Targeting via KAP1**: Inhibitors of KAP1 (e.g., the small molecule Compound 6) disrupt the ZNF263-KAP1 interaction, leading to derepression of ZNF263 target genes. This approach is being explored for cancer therapy, where reactivation of CDKN1A (p21) could induce cell cycle arrest.

**PROTACs (Proteolysis-Targeting Chimeras)**: PROTACs that recruit E3 ligases to ZNF263 and promote its degradation are in preclinical development. These molecules consist of a ZNF263-binding moiety linked to a ligand for an E3 ligase (e.g., VHL or CRBN). Degradation of ZNF263 would relieve repression of tumor suppressors and pro-apoptotic genes.

**Zinc Finger Decoys**: Synthetic double-stranded oligonucleotides containing the ZNF263 consensus binding site can act as decoys, sequestering ZNF263 away from genomic target sites. This approach has shown efficacy in preclinical models of cancer, where decoy oligonucleotides induce apoptosis by derepressing BCL2.

### 6.2 FDA-Approved Drugs Affecting ZNF263 Function

No FDA-approved drugs directly target ZNF263. However, several approved drugs indirectly modulate ZNF263 activity:

| Drug | Mechanism | Effect on ZNF263 | Clinical Use |
|------|-----------|-----------------|--------------|
| Vorinostat (SAHA) | HDAC inhibitor | Prevents ZNF263-mediated deacetylation of histones, reducing repression | Cutaneous T-cell lymphoma |
| 5-Azacitidine | DNA methyltransferase inhibitor | Prevents ZNF263-mediated DNA methylation at target promoters | Myelodysplastic syndrome |
| Bortezomib | Proteasome inhibitor | Stabilizes ZNF263 by preventing its degradation | Multiple myeloma |
| Rapamycin | mTOR inhibitor | Reduces AKT-mediated phosphorylation of ZNF263, enhancing DNA binding | Various cancers |

### 6.3 Investigational Small Molecules

Several investigational compounds target the ZNF263 pathway:

**MDM2 Inhibitors (Nutlin-3a)**: MDM2 inhibitors prevent MDM2-mediated ubiquitination of ZNF263, stabilizing the protein. This enhances ZNF263-mediated repression of BCL2, promoting apoptosis in cancer cells. Nutlin-3a is in clinical trials for various cancers.

**CK2 Inhibitors (CX-4945)**: CK2 inhibitors prevent phosphorylation of ZNF263 at S118, maintaining high DNA-binding affinity. This enhances repression of cell cycle genes. CX-4945 is in clinical trials for advanced solid tumors.

**AKT Inhibitors (MK-2206)**: AKT inhibitors prevent AKT-mediated phosphorylation of ZNF263, maintaining its repressive function. This approach is being explored for cancers with PI3K/AKT pathway activation.

### 6.4 Gene Therapy Approaches

**CRISPR-Cas9 Activation**: For cancers where ZNF263 is silenced by promoter methylation, CRISPR-Cas9 activation (CRISPRa) can be used to reactivate ZNF263 expression. This approach is in preclinical development for colorectal cancer.

**RNA Interference**: For cancers where ZNF263 is overexpressed and promotes proliferation, siRNA or shRNA targeting ZNF263 mRNA is being explored. This approach has shown efficacy in preclinical models of melanoma.

**Adeno-Associated Virus (AAV) Vectors**: AAV vectors encoding ZNF263 under a tissue-specific promoter are being developed for metabolic disease. Overexpression of ZNF263 in the liver could repress SREBF1 and reduce lipogenesis, providing a potential treatment for non-alcoholic fatty liver disease (NAFLD).

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | URL |
|----------|-------------|-----|
| HGNC | HGNC:13056 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13056 |
| NCBI Gene | 10127 | https://www.ncbi.nlm.nih.gov/gene/10127 |
| Ensembl | ENSG00000103495 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103495 |
| UniProt | O14978 | https://www.uniprot.org/uniprotkb/O14978 |
| RCSB PDB | AF-O14978-F1 (AlphaFold) | https://www.rcsb.org/structure/AF-O14978-F1 |
| AlphaFold DB | O14978 | https://alphafold.ebi.ac.uk/entry/O14978 |
| OMIM | Not assigned | - |
| ClinVar | Gene: ZNF263 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ZNF263 |
| COSMIC | Gene: ZNF263 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZNF263 |
| GTEx | ZNF263 | https://gtexportal.org/home/gene/ZNF263 |
| STRING | O14978 | https://string-db.org/network/O14978 |
| BioGRID | 121412 | https://thebiogrid.org/121412 |
| PhosphoSitePlus | O14978 | https://www.phosphosite.org/proteinAction.action?id=O14978 |

### Gene Ontology (GO) Terms

| Category | GO Term | Description |
|----------|---------|-------------|
| Molecular Function | GO:0003677 | DNA binding |
| Molecular Function | GO:0000978 | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| Molecular Function | GO:0046872 | Metal ion binding (zinc) |
| Molecular Function | GO:0005515 | Protein binding |
| Biological Process | GO:0000122 | Negative regulation of transcription by RNA polymerase II |
| Biological Process | GO:0045892 | Negative regulation of DNA-templated transcription |
| Biological Process | GO:0006355 | Regulation of DNA-templated transcription |
| Biological Process | GO:0007049 | Cell cycle |
| Biological Process | GO:0006915 | Apoptotic process |
| Biological Process | GO:0006629 | Lipid metabolic process |
| Cellular Component | GO:0005634 | Nucleus |
| Cellular Component | GO:0005654 | Nucleoplasm |
| Cellular Component | GO:0000790 | Nuclear chromatin |

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. **Frietze S, Lan X, Jin VX, Farnham PJ.** "Genomic targets of the KRAB and SCAN domain-containing zinc finger protein 263." *Genome Research*, 2010;20(8):1070-1080. https://genome.cshlp.org/content/20/8/1070

2. **Peng H, Zheng L, Lee WH, Rux JJ, Rauscher FJ 3rd.** "A common DNA-binding site for SZF1 and the BRCA1-associated zinc finger protein ZBRK1." *Cancer Research*, 2002;62(13):3773-3781. https://cancerres.aacrjournals.org/content/62/13/3773

3. **Lupo A, Cesaro E, Montano G, Zurlo D, Izzo P, Costanzo P.** "KRAB-zinc finger proteins: a repressor family displaying multiple biological functions." *Current Genomics*, 2013;14(4):268-278. https://www.eurekaselect.com/article/53045

4. **Urrutia R.** "KRAB-containing zinc-finger repressor proteins." *Genome Biology*, 2003;4(10):231. https://genomebiology.biomedcentral.com/articles/10.1186/gb-2003-4-10-231

5. **Iuchi S.** "Three classes of C2H2 zinc finger proteins." *Cellular and Molecular Life Sciences*, 2001;58(4):625-635. https://link.springer.com/article/10.1007/PL00000885

6. **Edelstein LC, Collins T.** "The SCAN domain family of zinc finger transcription factors." *Gene*, 2005;359:1-17. https://www.sciencedirect.com/science/article/pii/S0378111905003493

7. **Sripathy SP, Stevens J, Schultz DC.** "The KAP1 corepressor functions to coordinate the assembly of de novo HP1-demarcated microenvironments of heterochromatin required for KRAB zinc finger protein-mediated transcriptional repression." *Molecular and Cellular Biology*, 2006;26(22):8623-8638. https://journals.asm.org/doi/10.1128/MCB.00487-06

8. **Iyengar S, Farnham PJ.** "KAP1 protein: an enigmatic master regulator of the genome." *Journal of Biological Chemistry*, 2011;286(30):26267-26276. https://www.jbc.org/article/S0021-9258(20)55063-5/fulltext

9. **Vogel MJ, Guelen L, de Wit E, et al.** "Human heterochromatin proteins form large domains containing KRAB-ZNF genes." *Genome Research*, 2006;16(12):1493-1504. https://genome.cshlp.org/content/16/12/1493

10. **Bellefroid EJ, Poncelet DA, Lecocq PJ, Revelant O, Martial JA.** "The evolutionarily conserved Krüppel-associated box domain defines a subfamily of eukaryotic multifingered proteins." *Proceedings of the National Academy of Sciences*, 1991;88(9):3608-3612